BAJAJHCARE

Current scenario - Revenue from operations grew 18.9% YoY to INR175.9 crores and PAT grew 26.9% YoY in Q2 FY27. - Formulation business rebounded strongly, growing 82% YoY; API exports grew 28.5% YoY. - Company received NCLT approval for the acquisition of Genrx Pharmaceuticals Private Limited and DCGI approval for Cenobamate API tablets. Management Guidance & Outlook - Aiming to reach a revenue of INR900 crores to INR1,000 crores by FY29 with an EBITDA margin of 18% to 21%. - Expected capex for FY27 is INR65 crores to INR80 crores, with subsequent annual capex of INR50 crores to INR60 crores. - Formulations expected to contribute 45% to 50% of total revenue in the next 3 to 4 years. Capex & Expansion - Commercial peptide manufacturing plant with 250 kg per annum capacity scheduled to complete by March 31, 2027. - Oncology API plant expected to commence in Q2 FY28. - Dedicated formulation plant at Nashik expected to be operational by Q1 FY28.

- Bajaj Healthcare Limited has informed the exchange regarding the audio recording of the earnings call for Q2 & H1 FY27 held on October 19, 2026. - The recording has been made available on the company website.

- Q2 FY27 Revenue from operations up 18.9% YoY to ₹175.9 Cr. - EBITDA grew 12.2% YoY to ₹32.1 Cr; PAT increased 26.9% YoY to ₹14.1 Cr. - India Ratings upgraded long-term rating to IND A/Stable. - Peptide facility remains on track for commissioning in Q4 FY27.

Q2 FY27 Standalone Revenue ₹176.90 Cr vs ₹147.91 Cr (▲19.6% YoY) EBITDA ₹31.21 Cr vs ₹26.95 Cr (▲15.8% YoY) PAT ₹14.09 Cr vs ₹11.11 Cr (▲26.8% YoY) EBITDA Margin 17.64% vs 18.22% (▼58bps)

Bajaj Healthcare Limited received an order from the Hon'ble NCLT, Mumbai Bench on October 13, 2026. The order approves the acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis. Genrx Pharmaceuticals Private Limited will become a Wholly Owned Subsidiary of the company upon implementation. Trading window continues to remain closed for designated persons.

Concall Schedule Concall Date: Monday, 19th October 2026 Concall Time: 5:00 PM IST Purpose: To discuss the financial performance for Q2 & H1 FY27.

- Bajaj Healthcare Limited executed a Deed of Assignment on October 12, 2026, to sell an undertaking located at Dahej Industrial Area, GIDC, Bharuch, Gujarat. - The total consideration for the transaction is approximately ₹14.67 Crores. - The buyers are Spa Vet Private Limited and Indosol Pure Technologies Private Limited, and the transaction is not a related party transaction. - The undertaking was non-operational during the last financial year, resulting in Nil turnover contribution.

- The trading window for dealing in Bajaj Healthcare Limited securities will close from October 01, 2026. - It will reopen 48 hours after the declaration of un-audited financial results for the quarter and half year ended September 30, 2026.

- Bajaj Healthcare Limited declared a Final Dividend of 30% (₹1.50/- per equity share) for FY 2025-26. The Record Date for determining shareholder entitlement is September 14, 2026.